Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adverse Events
Biotech
Dyne shakes up C-suite after hazy DMD data drop
Dyne Therapeutics has revealed new phase 1/2 data on its Duchenne muscular dystrophy therapy DYNE-251, including several serious TEAEs.
Fraiser Kansteiner
Sep 3, 2024 11:49am
Galapagos pauses CAR-T cell therapy trial over Parkinsonism case
Aug 2, 2024 8:49am
ASCO: J&J's radioligand spurs responses, but 4 deaths mar data
May 24, 2024 10:51am
Merck halts phase 3 melanoma TIGIT trial due to discontinuations
May 13, 2024 8:39am
MacroGenics' stock crashes after 5 deaths in ADC trial
May 10, 2024 6:00am
FDA questions benefit-risk profile of Geron's imetelstat
Mar 12, 2024 12:20pm
